VivoSim Signs Seven-Figure Pharma Deal, Sees FY2027 Growth Above 500%
VIVS sits 30% above its 52-week low of $0.118 on light trading volume (0.3× avg).
Summary
VivoSim signed a seven-figure paid program-work agreement with a top-10 global pharmaceutical company, converting a large customer from evaluation to paid work, and the stock surged 82% premarket on the news. Management also said fiscal 2027 revenue growth should exceed its prior 500%+ guidance, though it gave no revised percentage or prior-period revenue comparison. Both toxicology service lines grew in the September quarter, but no rates or revenue figures were disclosed. The contract value is undisclosed, so revenue visibility stays thin — this is a micro-cap that just posted its first service revenue of $22K in fiscal Q2 with $8.6M of cash and going-concern doubt, and it still faces a Nasdaq $1 minimum bid compliance issue plus an approved reverse split. The deal is a real commercial step, but the size of the contribution is what determines whether it matters.
At the time of this announcement, VIVS was trading at $0.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.12 to $3.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.